| abstract |
The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of chronic obstructive pulmonary disease containing homoegonol as an active ingredient, and more particularly to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease wherein the homoeegonol is a tobacco extract- The expression of MCP-2, which promotes the migration of inflammatory cells, and TNF-α, an inflammatory cytokine, were suppressed, and the number of inflammatory cells in the lung tissue was reduced Lt; / RTI > Therefore, homoegonol effectively inhibits the inflammatory response in lung tissue through inhibition of inflammatory mediators, and thus can be effectively used as an effective ingredient of a pharmaceutical composition for the prophylaxis and treatment of chronic obstructive pulmonary disease. |